CBD for Neuropathic Pain in Diabetic Foot Neuropathy
Group 1. Complete formula
+ Group 2. Cannabidiol and Urea 10% formula.
+ Group 3. Placebo formula.
Cardiovascular Diseases+21
+ Diabetes Mellitus
+ Diabetic Angiopathies
Treatment Study
Summary
Study start date: November 1, 2024
Actual date on which the first participant was enrolled.This clinical study focuses on examining how cannabidiol (CBD), a compound derived from cannabis, can help reduce neuropathic pain in individuals suffering from diabetic foot neuropathy. This condition often causes severe pain and discomfort due to nerve damage associated with diabetes. The study aims to provide insights into whether CBD can be an effective treatment option for managing this type of pain, which could lead to better quality of life for those affected by diabetic foot syndrome. Additionally, the study looks at how using urea 10% cream might improve the skin quality of patients with this condition. Participants in the study receive treatments to assess their effects on neuropathic pain and skin health. The CBD is administered to see how it influences pain levels, while the urea 10% cream is applied to evaluate any improvements in the skin's condition. The study is designed to ensure neither the participants nor the researchers know who receives the actual treatment or a placebo, making it triple-blind. This helps ensure unbiased results. While the study does not specify the exact method of CBD administration, such studies typically involve oral or topical forms. The research does not explicitly mention risks or benefits, but the potential to alleviate pain and improve skin health is a significant focus.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.23 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.3 intervention groups are designated in this study
33.333% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Facultad de Enfermería, Fisioterapia y Podología de la Universidad Complutense de Madrid
Madrid, SpainOpen Facultad de Enfermería, Fisioterapia y Podología de la Universidad Complutense de Madrid in Google Maps